Clinical Hours: Mon-Fri, 8AM - 3PM(905) 493-5700
1885 Glenanna Road, Suite 220, Pickering, ON, L1V 6R6
A dermatologist explains why eczema cannot be permanently cured, what disease modification means, and how early biologic therapy may reshape the long-term course.
Few questions arise more often in the dermatology clinic than this one: can eczema be cured? The honest answer is nuanced. Atopic dermatitis is not an infection that can be eradicated, nor a transient irritation that disappears with a single course of cream. It is a chronic, relapsing inflammatory disease shaped by genetics, immune dysregulation, and environmental exposure. What has changed in the past decade, however, is the very concept of treatment success. The conversation has shifted from suppressing symptoms during flares to fundamentally altering the trajectory of the disease, an idea now described as disease modification.
Eczema has its roots in a combination of inherited and acquired factors. Mutations in the filaggrin gene compromise the skin barrier from birth, allowing irritants and allergens to penetrate more easily and triggering immune responses dominated by type 2 cytokines such as interleukin-4 and interleukin-13. The immune memory generated by this prolonged exposure persists. Even after the visible rash has cleared, the underlying biology that produced it remains primed to react. This is why clear skin does not equate to cured skin, and why discontinuing all therapy after a single successful course often leads to relapse.
The chronic nature of atopic dermatitis is also tied to its place within a broader sequence of allergic disease, sometimes called the atopic march. Children with early-onset moderate to severe eczema have an elevated risk of developing food allergies, asthma, and allergic rhinitis as the immune system continues to interpret harmless exposures as threats. The disease burden, therefore, is not confined to the skin.
A more detailed look at the underlying biology is available in the overview of eczema pathology, and a clinical summary of presentation and diagnosis is provided in the atopic dermatitis condition page.
Traditional eczema management has focused on disease control: reducing inflammation during flares, restoring the skin barrier, and minimizing the impact on sleep, mood, and daily function. Topical corticosteroids, calcineurin inhibitors, and emollients remain the foundation of this approach, as outlined in the review of Canadian topical eczema treatment options and the practical guide to daily eczema care.
Disease modification is a different goal. The term, borrowed from rheumatology and now applied to atopic dermatitis, refers to a treatment that alters the natural course of the disease rather than only suppressing its symptoms. A disease-modifying therapy aims for off-treatment remission, reduced relapse frequency, attenuation of comorbidities such as asthma and allergic sensitization, and changes in disease biology that persist after the medication has been stopped [1]. In atopic dermatitis, this represents a paradigm shift in how clinical trials are designed, how outcomes are measured, and how treatment decisions are framed.
What disease modification implies in practice. A drug that meets this standard does more than calm a flare. It reshapes the long-term trajectory of the condition by interrupting the inflammatory feedback loops that drive recurrence, barrier damage, and progression to other allergic disorders. The benefit is measured not only in clear skin today but in the cumulative course of the disease over years.
Inflammatory diseases tend to be most responsive to intervention before they have entrenched themselves. In rheumatoid arthritis, decades of evidence have established that early aggressive treatment changes the long-term course of joint disease. The same principle is now being investigated in atopic dermatitis.
The window of opportunity refers to a finite period, often early in the disease course and frequently in early childhood, during which the immune system retains enough plasticity to be redirected. Acting within this window may, in theory, prevent the consolidation of pathological immune memory, reduce the cumulative damage to the skin barrier, and lower the risk of progression along the atopic march. Allowing inflammation to persist, by contrast, may permit the disease to consolidate features that become harder to reverse later [1].
This concept is not yet a basis for routine guideline-driven decisions, and it remains an area of active investigation. It is, however, reshaping how dermatologists and immunologists think about timing. A child with severe, persistent eczema in the first years of life is no longer regarded simply as a patient with a difficult skin condition. That child carries a window during which the disease is potentially most modifiable, and missing that window may carry consequences beyond the immediate symptoms.
The arrival of targeted biologic therapies has provided the first plausible tools to test the disease-modification hypothesis in atopic dermatitis. These agents are monoclonal antibodies that block specific cytokine signals known to drive the disease. Unlike broad immunosuppressants, they intervene with precision in the type 2 inflammatory pathway that sits at the centre of atopic dermatitis biology [2].
Dupilumab. Dupilumab blocks the shared receptor for interleukin-4 and interleukin-13, the two cytokines most central to type 2 inflammation in eczema. It was the first biologic approved for moderate to severe atopic dermatitis and remains the best studied. Beyond improving the rash and itch, a 2024 population-based cohort study of pediatric patients reported that dupilumab was associated with a significant reduction in the cumulative incidence of atopic march progression compared with conventional immunomodulatory therapy [3]. This is among the strongest clinical signals to date that a targeted therapy can blunt downstream allergic disease, not only its cutaneous component.
Tralokinumab and lebrikizumab. These two newer biologics target interleukin-13 specifically. Both have demonstrated meaningful improvements in disease severity, itch, and quality of life in moderate to severe atopic dermatitis, and long-term data suggest sustained response in a substantial proportion of patients who continue therapy [2]. They expand the range of options available for patients who cannot tolerate or do not respond adequately to dupilumab.
Nemolizumab. Nemolizumab inhibits the interleukin-31 receptor, a key driver of the itch sensation in atopic dermatitis and prurigo nodularis. By targeting itch at its neurological root, it addresses one of the most distressing symptoms of the disease and complements the inflammation-targeting effects of the other biologics [2].
JAK inhibitors. Oral Janus kinase inhibitors such as upadacitinib, and abrocitinib block several downstream cytokine pathways simultaneously. They are particularly rapid in onset and have a distinct safety profile that requires careful patient selection and monitoring [4]. Topical JAK inhibitors, including ruxolitinib cream, expand the toolkit further for milder disease and for patients who prefer a non-systemic option.
Together with the foundation of barrier care and topical anti-inflammatories, these therapies are now considered standard of care for moderate to severe atopic dermatitis that has not responded adequately to topical therapy alone [4][5]. Detailed information on these agents and how they are used in this practice is available at the page on biologic and advanced small molecule therapy.
The honest reality is that eczema, as currently understood, cannot be cured in the way that an infection can be cured. The genetic and immunological factors that produced the disease cannot be erased, and even the most effective biologic therapies are control measures that work while they are being taken. Stopping therapy abruptly often leads to recurrence.
What has changed is the depth and durability of the control that is now possible, and the early indication that timely use of targeted therapy may reshape the long-term course of the disease in selected patients. The conversation about eczema is no longer limited to whether the rash is visible today. It now includes whether long-term remission is achievable, whether the atopic march can be slowed, and whether intervention during a critical window can produce changes that outlast the treatment itself.
For patients living with moderate to severe atopic dermatitis, especially when symptoms began in early life or are accompanied by allergic comorbidities, this is a meaningful shift. A treatment plan that was once a quest to suppress flares may, in the right context, become a strategy aimed at altering the disease itself.
A consultation at the Centre for Medical and Surgical Dermatology allows for an individualized dermatology assessment of disease severity, comorbidities, and treatment options, including whether biologic or advanced small molecule therapy may be appropriate in a given case.
This article is intended for educational purposes and does not replace professional medical advice. Please consult your dermatologist for personalized recommendations.
Your feedback helps us improve our news and clinical insights
From medical dermatology to surgical procedures, our clinic provides comprehensive care for all skin, hair, and nail conditions.